HC Wainwright Has Negative Outlook of SLN FY2024 Earnings

Silence Therapeutics plc (NASDAQ:SLN) – HC Wainwright dropped their FY2024 earnings per share estimates for shares of Silence Therapeutics in a note issued to investors on Wednesday, January 29th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($1.73) per share for the year, down from their prior estimate of ($1.60). HC Wainwright has a “Buy” rating and a $75.00 price target on the stock. The consensus estimate for Silence Therapeutics’ current full-year earnings is ($1.75) per share. HC Wainwright also issued estimates for Silence Therapeutics’ Q4 2024 earnings at ($0.41) EPS, Q1 2025 earnings at ($0.44) EPS, Q2 2025 earnings at ($0.53) EPS, Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.73) EPS, FY2025 earnings at ($2.30) EPS, FY2026 earnings at ($2.56) EPS, FY2027 earnings at ($2.28) EPS and FY2028 earnings at ($0.41) EPS.

A number of other analysts have also weighed in on the stock. BMO Capital Markets reiterated an “outperform” rating on shares of Silence Therapeutics in a report on Monday, December 2nd. William Blair restated an “outperform” rating on shares of Silence Therapeutics in a report on Tuesday, November 19th. Chardan Capital reiterated a “buy” rating and issued a $55.00 price target on shares of Silence Therapeutics in a report on Tuesday, December 10th. Finally, Morgan Stanley reissued an “overweight” rating and set a $49.00 price objective on shares of Silence Therapeutics in a research report on Tuesday, October 8th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, Silence Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $54.75.

Silence Therapeutics Stock Up 1.5 %

Shares of NASDAQ:SLN opened at $5.33 on Monday. The stock has a market cap of $159.53 million, a PE ratio of -3.39 and a beta of 1.08. The company’s fifty day moving average is $6.60 and its 200 day moving average is $13.74. Silence Therapeutics has a 52 week low of $4.82 and a 52 week high of $27.72.

Institutional Trading of Silence Therapeutics

Several hedge funds have recently bought and sold shares of SLN. Eventide Asset Management LLC purchased a new position in Silence Therapeutics during the third quarter worth $11,635,000. Millennium Management LLC grew its holdings in shares of Silence Therapeutics by 91.2% in the second quarter. Millennium Management LLC now owns 782,941 shares of the company’s stock worth $14,876,000 after purchasing an additional 373,523 shares during the last quarter. Point72 Asset Management L.P. boosted its position in Silence Therapeutics by 219.3% in the 3rd quarter. Point72 Asset Management L.P. now owns 467,800 shares of the company’s stock valued at $8,505,000 after buying an additional 321,300 shares during the period. Janus Henderson Group PLC raised its stake in shares of Silence Therapeutics by 32.8% during the third quarter. Janus Henderson Group PLC now owns 1,087,228 shares of the company’s stock valued at $19,798,000 after acquiring an additional 268,250 shares in the last quarter. Finally, Parkman Healthcare Partners LLC grew its stake in Silence Therapeutics by 71.8% in the third quarter. Parkman Healthcare Partners LLC now owns 497,870 shares of the company’s stock worth $9,051,000 after purchasing an additional 208,029 shares in the last quarter. Hedge funds and other institutional investors own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.